ライフサイエンスコーパス: adjuvant radiotherapy

1 t received neoadjuvant treatment, 5 received adjuvant radiotherapy.

2 lant SR was higher in women who had received adjuvant radiotherapy.

3 hat AC is a potentially tractable target for adjuvant radiotherapy.

4 dict risk for LRR and to optimize the use of adjuvant radiotherapy.

5 minant tumors had an improved prognosis with adjuvant radiotherapy.

6 therapy and chemotherapy versus surgery plus adjuvant radiotherapy.

7 positive surgical margins) may benefit from adjuvant radiotherapy.

8 lity, underwent breast surgery, and received adjuvant radiotherapy.

9 ng proctosigmoidectomy (group 1: n = 101) or adjuvant radiotherapy (40-50 Gy) and resection (group 2:

10 After the completion of adjuvant radiotherapy (42.50 Gy in 16 fractions to the b

11 iotherapy, and finally, randomised trials of adjuvant radiotherapy after lymph-node dissection.

12 There is relatively little literature on adjuvant radiotherapy after radical nephroureterectomy w

13 ification of patients susceptible to receive adjuvant radiotherapy after surgery.

14 ) between breast cancer survivors exposed to adjuvant radiotherapy and chemotherapy (aRCeBCSs) for pr

15 Adjuvant radiotherapy and chemotherapy for breast cancer

16 herapy versus surgery alone, or surgery plus adjuvant radiotherapy and chemotherapy versus surgery pl

17 As compared with radiotherapy alone, adjuvant radiotherapy and chemotherapy with cisplatin an

18 We aimed to assess the effectiveness of adjuvant radiotherapy and tamoxifen.

19 lted in controversy about the optimal use of adjuvant radiotherapy and the timing of sentinel lymph n

20 Twelve patients (57%) received adjuvant radiotherapy, and 2 patients received chemother

21 juvant chemotherapy followed by enucleation, adjuvant radiotherapy, and chemotherapy.

22 h as the role of extrapleural pneumonectomy, adjuvant radiotherapy, and use of intensity-modulated ra

23 nted oncologic benefit, use of postoperative adjuvant radiotherapy (aRT) in patients with prostate ca

24 The role of adjuvant radiotherapy (aRT) in treating patients with pN

25 all or cause-specific survival advantage for adjuvant radiotherapy as compared with delayed salvage t

26 dectomy, most patients with seminoma receive adjuvant radiotherapy as standard of care, although surv

27 ular germ cell tumors have been managed with adjuvant radiotherapy, chemotherapy, or retroperitoneal

28 In conclusion, adjuvant radiotherapy did not offer any significant bene

29 New randomized trial data of adjuvant radiotherapy for high-risk disease have not dem

30 However, the use of adjuvant radiotherapy for high-risk nodal disease is inc

31 as the standard of care for women requiring adjuvant radiotherapy for invasive early breast cancer.

32 dy was designed to determine the efficacy of adjuvant radiotherapy for patients with pT3N0M0 UTUC.

33 t review to assess the optimal sequencing of adjuvant radiotherapy for such patients undergoing limb-

34 -free survival, 76 (35.5%) of 214 men in the adjuvant radiotherapy group were diagnosed with metastat

35 Therapies combined with adjuvant radiotherapy have been demonstrated to improve

36 reservation, the addition of chemotherapy to adjuvant radiotherapy, improvement in surgical and radia

37 randomised trials that confirm a benefit of adjuvant radiotherapy in patients with nodal disease at

38 ferences between those omitting vs receiving adjuvant radiotherapy in regards to 2-year rates of over

39 as and a good prognosis, and alternatives to adjuvant radiotherapy in stage I seminomas.

40 f this study was to determine whether modern adjuvant radiotherapy is associated with increased risk

41 Adjuvant radiotherapy is effective treatment for stage I

42 /or studied for most high-grade sarcomas and adjuvant radiotherapy is important for disease control i

43 ccurs at 2.5 years, when the initial cost of adjuvant radiotherapy is matched by the cost generated d

44 the 5-year biochemical recurrence rate using adjuvant radiotherapy may be decreased from approximatel

45 In this study, neither adjuvant radiotherapy nor salvage surgery was reliable i

46 tandard of care involved surgery followed by adjuvant radiotherapy or chemoradiotherapy.

47 r obtaining an additional PET/CT scan before adjuvant radiotherapy or concurrent chemoradiotherapy (C

48 vesicle invasion) were randomly assigned to adjuvant radiotherapy or observation.

49 t (P = .030), treatment year (P = .008), and adjuvant radiotherapy (P = .046).

50 ictors for PFS by multivariate analysis were adjuvant radiotherapy (P = 0.010; HR, 0.39; 95% CI, 0.20

51 for pathologically advanced prostate cancer, adjuvant radiotherapy resulted in significantly reduced

52 Adjuvant radiotherapy (RT) after a local excision (LE) f

53 Purpose To evaluate the effect of adjuvant radiotherapy (RT) after breast conservation sur

54 Adjuvant Radiotherapy (RT) after surgical removal of tum

55 S were treated with limb-sparing surgery and adjuvant radiotherapy (RT) at a single institution.

56 The benefit of adjuvant radiotherapy (RT) for gallbladder cancer remain

57 Adjuvant radiotherapy (RT) in breast cancer (BC) is ofte

58 Four randomized studies show that adjuvant radiotherapy (RT) lowers the risk of subsequent

59 d larynx treated with definitive surgery and adjuvant radiotherapy (RT) or CRT.

60 Adjuvant radiotherapy seems to improve local control and

61 ard refinements in the methods of delivering adjuvant radiotherapy that provide shorter, more conveni

62 en in an advanced-stage, intermediate-grade, adjuvant radiotherapy to bulky sites may improve outcome

63 le reviews the rationale and indications for adjuvant radiotherapy to the breast and regional lymph n

64 Adjuvant radiotherapy was discussed, but he elected to h

65 m RCTs demonstrates a survival detriment for adjuvant radiotherapy with limited evidence for a reduct

66 This ongoing trial examines the use of adjuvant radiotherapy with or without adjuvant androgen

67 Physicians should discuss adjuvant radiotherapy with patients with adverse patholo